Literature DB >> 18809944

Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.

Luis Ostrosky-Zeichner1, John H Rex, Michael A Pfaller, Daniel J Diekema, Barbara D Alexander, David Andes, Steven D Brown, Vishnu Chaturvedi, Mahmoud A Ghannoum, Cindy C Knapp, Daniel J Sheehan, Thomas J Walsh.   

Abstract

We investigated if CLSI M27-A2 Candida species breakpoints for fluconazole MIC are valid when read at 24 h. Analysis of a data set showed good correlation between 48- and 24-h MICs, as well as similar outcomes and pharmacodynamic efficacy parameters, except for isolates in the susceptible dose-dependent category, such as Candida glabrata.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18809944      PMCID： PMC2573146          DOI： 10.1128/AAC.00420-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

4.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

Review 5.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

6.  Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans.

Authors:  D S Burgess; R W Hastings; K K Summers; T C Hardin; M G Rinaldi
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

7.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191
View more
  15 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; J Peter Donnelly; Cornelia Lass-Flörl; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-06       Impact factor: 5.191

3.  Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Authors:  Shawn R Lockhart; Carol B Bolden; Naureen Iqbal; Randall J Kuykendall
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

4.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

Review 5.  Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).

Authors:  Edinaira Sulany Oliveira de Sousa; Ana Claúdia Alves Cortez; Marcia de Souza Carvalho Melhem; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-08-05       Impact factor: 2.476

6.  Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.

Authors:  Jesús Guinea; Sandra Recio; Pilar Escribano; Marta Torres-Narbona; Teresa Peláez; Carlos Sánchez-Carrillo; Marta Rodríguez-Créixems; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

7.  Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

Authors:  M Puig-Asensio; M Fernández-Ruiz; J M Aguado; P Merino; D Lora-Pablos; J Guinea; P Martín-Dávila; M Cuenca-Estrella; B Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

9.  Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; M G Rinaldi; A W Fothergill
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

10.  Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.

Authors:  Brunella Posteraro; Rosa Martucci; Marilena La Sorda; Barbara Fiori; Dominique Sanglard; Elena De Carolis; Ada Rita Florio; Giovanni Fadda; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.